Fennec Pharmaceuticals Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $44.6M | $47.5M | $21.3M | $1.5M | $170.0K | $0 | $0 | $0 |
| Cost of Revenue | — | — | $1.3M | $86.0K | — | — | — | — |
| Gross Profit | — | — | $20.0M | $1.4M | — | — | — | — |
| Gross Margin | — | — | 94.1% | 94.4% | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $250.0K | $307.0K | $56.0K | $3.5M | $5.1M | $5.6M | $5.0M | $1.9M |
| SG&A Expense | $28.3M | $23.1M | $20.6M | $17.7M | $13.0M | $7.4M | $5.4M | $5.0M |
| Operating Income | $-6.3M | $2.6M | $-12.8M | $-22.6M | $-17.9M | $-13.0M | $-10.4M | $-7.0M |
| Operating Margin | -14.1% | 5.4% | -60.1% | -1,471.6% | -10,520.6% | — | — | — |
| Interest Expense | $2.1M | $4.1M | $3.4M | — | — | — | — | — |
| Pretax Income | $-9.6M | $-71.0K | $-16.0M | — | — | — | — | $-7.0M |
| Income Tax Expense | $106.0K | $365.0K | — | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-9.7M | $-436.0K | $-16.0M | $-23.7M | $-18.1M | $-12.8M | $-9.9M | $-7.0M |
| Net Margin | -21.8% | -0.9% | -75.5% | -1,544.9% | -10,652.4% | — | — | — |
| EPS (Basic) | $-0.34 | $-0.02 | $-0.60 | $-0.90 | $-0.76 | $-0.64 | $-0.52 | $-0.47 |
| EPS (Diluted) | $-0.34 | $-0.02 | $-0.60 | $-0.90 | $-0.76 | $-0.64 | $-0.52 | $-0.47 |
| Shares Outstanding (Basic) | 28.6M | 27.3M | 26.6M | 26.3M | 23.7M | 19.9M | 18.9M | 15.0M |
| Shares Outstanding (Diluted) | 28.6M | 27.3M | 26.6M | 26.3M | 23.7M | 19.9M | 18.9M | 15.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |